Global Hepatitis E Diagnostic Tests Market

Hepatitis E virus is the leading cause of acute viral hepatitis in the world mainly affecting the liver. HEV is considered a travel-associated infection. Diagnosis of HEV is based on the detection of viral RNA in the serums or feces. There is no specific treatment for hepatitis E. Analysis of HEV performed on RNA in biologic specimens such as liver biopsy, stools, and serums are used for diagnostics. Further, the government and health authorities of various countries are also taking various efforts for making diagnostic tests available in the countries. A world Health Organization is focusing on making vaccines and diagnostic tests available to reduce the global burden of disease. Also, the key players are focusing on strategies such as product launch, innovation, and merger & acquisition to sustain themselves amidst fierce competition. The growth of the market is attributed owing to the increase in rising the prevalence of hepatitis-e disease along with the government initiative regarding awareness of hepatitis E diagnosis. As per the World Health Organization in July 2020, every year there were an estimated 20 million HEV infections worldwide, leading to 3.3 million symptomatic cases of hepatitis E. As a result, the need for hepatitis e diagnostic tests would increase thereby, reinforcing the growth of the market during the forecast period of 2020-2027. However, the high cost of diagnostics procedures and poor reimbursement policies may hinder the growth of the global Hepatitis E diagnostic tests market.

Global Hepatitis E Diagnostic Tests Market is valued at approximately USD 50.00 million in 2019 and is anticipated to grow with a healthy growth rate of more than 4.50 % over the forecast period 2020-2027 and is estimated to reach USD 71.10 million by 2027.

The regional analysis of the global market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and the Rest of the World. Asia-pacific is the leading/significant region due to the increasing incidence of HEV in some countries such as Nepal, Vietnam, Pakistan, Bangladesh, Burma, Kazakhstan, Thailand, and Bhutan of this region. Also, the dominance of the region is witnessed owing to the lack of proper sanitation and access to safe drinking water which may cause Hepatitis E. Whereas Asia-Pacific is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027.

Major market players included in this report are Altona Diagnostics GmbH, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, Biokit S.A., Dia.Pro – Diagnostic Bioprobes s.r.l, F. Hoffmann-La Roche Ltd., Fast-track diagnostics Ltd., Fortress Diagnostics Limited, Mikrogen GmBH, MP Biomedicals, LLC., and Primerdesign Ltd.

The detailed segments and sub-segment of the market are explained below:

By Test Type: HEV IgM ELISA Test kits, HEV IgG ELISA Test kits, RT-PCR Test kits, Others

By End-User: Hospitals, Diagnostic Laboratories, Research Centers, Point of Care

Review our report at
To review more reports on Upcoming topics, visit us at

Data drives better decisions
Bizwit Research & Consulting LLP